Evidence map›Paper›PMID 37684549›Full record

ArticleCancer gene therapy2023

Clonal dynamics limits detection of selection in tumour xenograft CRISPR/Cas9 screens.

Tet Woo Lee, Francis W Hunter, Peter Tsai, Cristin G Print, William R Wilson, Stephen M F Jamieson

Open access · hybridAbstract read
In one paragraph

Article in Cancer gene therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Tet Woo LeeAuckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand. tw.lee@auckland.ac.nz.ORCID 0000-0002-2744-1784
Francis W HunterAuckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand.
Peter TsaiMaurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand.
Cristin G PrintMaurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand.
William R WilsonAuckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand.ORCID 0000-0002-9939-8738
Stephen M F JamiesonAuckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand. s.jamieson@auckland.ac.nz.ORCID 0000-0002-5485-9211
University of Auckland · NZ

Funding

Auckland Medical Research Foundation (AMRF) 1115022Manatu Hauora | Health Research Council of New Zealand (HRC) 14/538Manatu Hauora | Health Research Council of New Zealand (HRC) 19/433
6 · The paper itself

Abstract

Transplantable in vivo CRISPR/Cas9 knockout screens, in which cells are edited in vitro and inoculated into mice to form tumours, allow evaluation of gene function in a cancer model that incorporates the multicellular interactions of the tumour microenvironment. To improve our understanding of the key parameters for success with this method, we investigated the choice of cell line, mouse host, tumour harvesting timepoint and guide RNA (gRNA) library size. We found that high gRNA (80-95%) representation was maintained in a HCT116 subline transduced with the GeCKOv2 whole-genome gRNA library and transplanted into NSG mice when tumours were harvested at early (14 d) but not late time points (38-43 d). The decreased representation in older tumours was accompanied by large increases in variance in gRNA read counts, with notable expansion of a small number of random clones in each sample. The variable clonal dynamics resulted in a high level of 'noise' that limited the detection of gRNA-based selection. Using simulated datasets derived from our experimental data, we show that considerable reductions in count variance would be achieved with smaller library sizes. Based on our findings, we suggest a pathway to rationally design adequately powered in vivo CRISPR screens for successful evaluation of gene function.

Indexed as

CRISPR-Cas SystemsGene EditingAgedAnimalsClone CellsHeterograftsHumansMiceRNA, Guide, CRISPR-Cas SystemsRNA, Guide, CRISPR-Cas Systems

Identifiers

PMID37684549
PMCPMC10721547
OpenAlexW4386545365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.